Pharmaceuticals
Nippon Express (UK) Receives IATA CEIV Pharma Certification for Its Facility in Heathrow Airport Suburb
TOKYO, April 25, 2023 /PRNewswire/ -- Nippon Express (UK) Ltd. (hereinafter "NXUK"), a group company of NIPPON EXPRESS HOLDINGS, INC., has been awarded IATA CEIV Pharma certification*, a quality certificate for pharmaceutical transport established by the International Air Transport Association (I...
2023-04-25 15:00
2420
I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon
* Award is an important victory for I-Mab and its shareholders on multiple levels, ending the multi-year long dispute * Tribunal completely denied Tracon's groundless damages claim of over $200 million relating to I-Mab's next-generation bi-specific antibody assets and awarded no damages to T...
2023-04-25 13:46
1832
Biotech firm Gene Solutions: A promising picture for multi-cancer early detection in Southeast Asia
HO CHI MINH CITY, Vietnam, April 25, 2023 /PRNewswire/ -- In January 2023,
Vietnam's Medical Genetics Institute & Gene Solutions
2023-04-25 12:00
2162
Ascentage Pharma Passes GMP Compliance Audit by EU QP with Zero Deficiency, in an Achievement Signaling Global Recognition of the Company's Quality Management System
SUZHOU, China and ROCKVILLE, Md., April 24, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it recently received a zero-deficiency repor...
2023-04-25 08:42
1864
I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China
GAITHERSBURG, Md. and SHANGHAI, April 24, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the first patient in a Phase 3 registrational tri...
2023-04-24 21:00
1948
BIORCHESTRA Announces Significant Progress in Studies of BMD-001 Drug Program
* Encouraging non-human primate (NHP) findings support the progression of IV-formulatedBMD-001 ahead of formal clinical studies for Alzheimer's disease, Amyotrophic Lateral Sclerosis, and Parkinson's disease * Further validation of Brain Targeting RNAi Nanomedicine (BTRiNTM), including target...
2023-04-24 20:00
1409
Four innovative drugs launched in three years, HKEX -Listed Simcere Pharmaceutical Group is on the Fast Track Toward Building an Innovation-Driven Global Pharmaceutical Company
-The revenue from innovative drugs accounted for more than 65% of total revenue -Simcere's total revenue and the revenue from innovative drugs hit record highs. NANJING, China, April 24, 2023 /PRNewswire/ -- On Apr. 18, Simcere Pharmaceutical (2096.HK) disclosed the latest progress on the compa...
2023-04-24 18:09
2409
Tibetan medicine advanced over past decade
BEIJING, April 24, 2023 /PRNewswire/ -- A news report from chinadaily.com.cn: Adhering to an equal emphasis on traditional Chinese and Western medicine, the government of the Tibet autonomous region has increased financial investment, formulated supportive policies and promoted the development of...
2023-04-24 17:04
1398
Daewoong Pharmaceutical Announce Publication of Phase 3 Study of 'Envlo', a New Treatment for Diabetes, in the International SCIE Journal
SEOUL, South Korea, April 24, 2023 /PRNewswire/ -- The research results of Daewoong Pharmaceutical's SGLT-2 inhibitor new drug, 'Envlo', have been internationally acknowledged. On April 4, Daewoong Pharmaceutical (CEO Seng-ho Jeon and Chang-jae Lee) announced that the efficacy and safety evalu...
2023-04-24 14:53
2391
Samsung Biologics Reports First Quarter 2023 Financial Results
* Recorded Q1'23 consolidated revenue of KRW 720.9 billion. * Recorded Q1'23 consolidated operating profit of KRW 191.7 billion. * Expected to maintain a strong growth trajectory with the full utilization of existing and newly expanded capacities. INCHEON, South Korea, April 24, 2023 /PRNews...
2023-04-24 14:51
2290
Belief BioMed Announces a Key Milestone of Dosing Completion for All Subjects in its Registrational Clinical Trial of BBM-H901
SHANGHAI, April 24, 2023 /PRNewswire/ -- Belief BioMed Group (BBM), an industry-leading biotech company focusing on innovative gene therapies, announced today the completion of patient dosing in its Phase III Registrational Clinical Trial (CTR20212816) of BBM-H901, a gene therapy for Hemophilia ...
2023-04-24 10:23
2468
SCG Cell Therapy to Present Late-Breaking Data at the International Society for Cell & Gene Therapy (ISCT) Highlighting Promising Antitumor and Antiviral Activities of SCG101 in Treating HBV-Related Hepatocellular Carcinoma
SINGAPORE, April 24, 2023 /PRNewswire/ -- Singapore based SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, today announced that late-breaking data from the company's TCR-T therapy pipeline...
2023-04-24 10:00
2329
Patsnap Unveils Synapse Visitor, the Latest AI-Powered Pharmaceutical Intelligence Platform
LONDON, April 23, 2023 /PRNewswire/ -- On April 20, Patsnap, the world's leading SaaS provider for intelligence, announced the launch of its latest version of the intelligence platform, Synapse, available to visitors. This version includes advanced search functions for drugs and pharmaceutical o...
2023-04-24 08:00
2642
Everest Medicines Launches Nefecon in China's Hainan Boao Pilot Zone as a First-in-Disease Therapy for IgA Nephropathy
SHANGHAI, April 24, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest," or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today that Nefecon, the first-in-disease treatment fo...
2023-04-24 07:44
2719
ImmVira Appoints Dr. Oliver Kong as Chief Medical Officer
SHENZHEN, China, April 20, 2023 /PRNewswire/ -- On April 17, 2023, ImmVira announced the appointment of Dr.Oliver Kong as Chief Medical Officer (CMO). Dr. Kong will be fully in charge of global clinical development and international collaboration of company pipelines, and participate in overall c...
2023-04-21 09:06
2137
LTS expands into large molecule drug delivery with the acquisition of the Sorrel wearable injection device business
ANDERNACH, Germany, April 21, 2023 /PRNewswire/ -- LTS LOHMANN Therapie-Systeme AG ("LTS"), a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches ("TTS"), Oral Thin Films ("OTF") and Micro Array Patches ("MAP") anno...
2023-04-21 00:00
2545
CARsgen's CAR T-cell Candidate CT041 Achieves IND Clearance from the NMPA for the Postoperative Adjuvant Therapy of Pancreatic Cancer
SHANGHAI, April 20, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced that CT041, an autologous CAR T-cell product candidate against the p...
2023-04-20 20:50
2413
Samyang Holdings Enters Partnership with LG Chem for the Development of Innovative Cancer Therapeutics
* Implementation of Samyang Holdings' drug delivery technology for the development of mRNA-based cancer therapeutics SEOUL, South Korea, April 20, 2023 /PRNewswire/ -- Samyang Holdings and LG Chem have announced their recent execution of strategic partnership agreement onThursday, April 20th, f...
2023-04-20 20:30
1786
BioMed Technology Funded by Alibaba Hong Kong Entrepreneurs Fund, Gobi and TIMC to Realise Precision and Personalised Gut Microbiome Management for Wellness
HONG KONG, April 20, 2023 /PRNewswire/ -- BioMed Technology Holdings Limited (BioMed),Hong Kong's leading microbiome startup, has raised USD 2 million in its latest oversubscribed seed round from Alibaba Hong Kong Entrepreneurs Fund (AEF), Gobi Partners GBA and The International Medical Co. Ltd. ...
2023-04-20 16:15
4525
Innovent Announces Overall Survival Results of Phase 2 Study of Pemazyre® (pemigatinib) in Chinese Patients with Advanced Cholangiocarcinoma Presented at AACR Annual Meeting 2023
ROCKVILLE, Md. and SUZHOU, China, April 20, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology a...
2023-04-20 08:00
4076
Week's Top Stories
Most Reposted
Agoda releases generative AI film to capture the joy of travel
[Picked up by 349 media titles]
2024-12-10 10:00
Singapore's IMAGINE AI: Largest Global Gathering to Shape the Future of Healthcare with AI Innovations
[Picked up by 316 media titles]
2024-12-06 10:41
Mastercard Economics Institute: APAC growth expected to hold steady in 2025; global policy resets may see shift in gears
[Picked up by 313 media titles]
2024-12-10 09:00Building Asia's Future: Omni HR Secures $7.4mn for HR Tech Expansion
[Picked up by 306 media titles]
2024-12-09 10:00
CCTV+: Yuhang Journey ǀ Follow Olivier to Explore Ancient Liangzhu and Savor Jingshan Tea
[Picked up by 283 media titles]
2024-12-08 20:07Most Read
Singapore's IMAGINE AI: Largest Global Gathering to Shape the Future of Healthcare with AI Innovations
2024-12-06 10:41
7011
Qi Biodesign Completes $75 Million in Total Funding to Drive Genome Editing Innovations
2024-12-06 20:15
6566
BROOKLYN NETS AND PHOENIX SUNS TO PLAY TWO PRESEASON GAMES IN MACAO IN OCTOBER 2025
2024-12-06 21:09
5801
